Cancer research
Researchers have made new findings in the field of oncology, specifically in the treatment of non-small cell lung cancer, by investigating the combination of telaglenastat and nivolumab. Telaglenastat, a glutaminase 1 inhibitor, targets the dysregulation in glutamine metabolism in cancer cells and the tumor microenvironment. A phase I/II trial
Cancer research
A new study published in the Journal of Investigative Medicine High Impact Case Reports has highlighted the exceptional long-term response of an African American man with mutated metastatic lung adenocarcinoma to immunotherapy treatment. The patient's response, which lasted over two years, has been attributed to his STK11/TP53
Cancer research
A recent study has shed new light on the benefits of consolidative chest radiotherapy after chemoimmunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). The research, published in the journal Discover Oncology, analyzed data from the National Cancer Database for patients diagnosed with ES-SCLC between 2017 and 2020. The
Cancer
Researchers from China Jiliang University have made significant progress in cancer immunotherapy by identifying neoantigens as key targets for eliminating cancer cells. According to a recent study published in the International Journal of Oncology, neoantigens are abnormal peptide fragments or protein segments uniquely expressed in tumor cells, making them highly
Cancer
New research out of India has shed light on the immense potential of cancer immunotherapy, with a focus on nucleic acid therapies that can modify immune responses and change the expression of target genes. According to a study published in the journal Advances in Immunology, the development of nanoparticle delivery
Cancer
Scientists at Taipei Medical University have developed a novel nanosystem that targets metastatic tumor cells and enhances cancer immunotherapy. The research, published in the Journal of Nanobiotechnology, presents a multifunctional nanoplatform that combines metal ions, organic ligands, and fucoidan to suppress tumor growth and distant metastasis. The nanocomplexes were shown
Cancer
Researchers have made significant advancements in cancer immunotherapy using mRNA-based therapeutics, which specifically target and eradicate cancer cells by utilizing the immune system. A study from Maharishi Markandeshwar (Deemed to be University) has highlighted the ability of mRNA to stimulate an immune response, increase its stability, and boost its ability
Cancer research
The metastatic prostate cancer market is witnessing a transformative shift towards precision medicine, driven by the development of targeted therapies, precision treatment approaches, and combination therapies. This trend is fueled by the increasing need for more effective and personalized treatments that improve patient outcomes and quality of life. Key players
Cancer
Researchers at the University of Michigan have made a significant advancement in cancer immunotherapy by designing a potent oral stimulator of interferon genes (STING) agonist, ZSA-215, which achieves complete tumor regression and long-term survival in mice. This breakthrough has the potential to revolutionize the treatment of various types of cancer,
Cancer
Researchers at the University of Washington conducted a prospective cohort study to assess whether paired normal-tumour testing increased access to targeted therapy, clinical trials, and influenced cancer screening recommendations for patients with gastric cancer. The study found that 76.2% of the 42 patients included in the study were eligible
Cancer
Researchers at New York University (NYU) have made significant progress in cancer gene therapy using a Sindbis viral (SV) vector platform. A new study published in the journal Pharmaceuticals has shown promising results in treating pancreatic cancer, a highly immunosuppressive and challenging disease. The study aimed to assess the treatment
Cancer
Cancer survivors often experience significant financial hardship due to the rising costs of novel immunotherapies, making it challenging for them to afford medical care. A recent study published in the Journal of Cancer Survivorship has examined the association between financial hardship and receipt of high-cost immunotherapy among cancer survivors. The
